AR069638A1 - Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas. proceso. - Google Patents

Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas. proceso.

Info

Publication number: AR069638A1
Authority: AR; Argentina
Prior art keywords: dione; dihydroxy; prop; alkyl; tetramethyl
Prior art date: 2007-12-10

Application number

ARP080105366A

Other languages

English (en)

Spanish (es)

Inventor

Katrin Fischer

Sascha General

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-10

Filing date

2008-12-10

Publication date

2010-02-10

2008-12-10 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2010-02-10 Publication of AR069638A1 publication Critical patent/AR069638A1/es

Links

239000002105 nanoparticle Substances 0.000 title abstract 13
229920000642 polymer Polymers 0.000 title abstract 6
238000000034 method Methods 0.000 title abstract 2
239000007787 solid Substances 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 12
239000001257 hydrogen Substances 0.000 abstract 12
125000003710 aryl alkyl group Chemical group 0.000 abstract 9
125000003118 aryl group Chemical group 0.000 abstract 9
150000002431 hydrogen Chemical group 0.000 abstract 9
-1 heteroaromatic radical Chemical class 0.000 abstract 8
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 7
125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 6
239000002245 particle Substances 0.000 abstract 6
229930013356 epothilone Natural products 0.000 abstract 5
239000002253 acid Substances 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 4
LZWPOLSJFGLQCE-UHFFFAOYSA-N heptadecane-5,9-dione Chemical compound CCCCCCCCC(=O)CCCC(=O)CCCC LZWPOLSJFGLQCE-UHFFFAOYSA-N 0.000 abstract 4
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 abstract 4
239000000203 mixture Substances 0.000 abstract 4
125000002091 cationic group Chemical group 0.000 abstract 3
239000000032 diagnostic agent Substances 0.000 abstract 3
229940039227 diagnostic agent Drugs 0.000 abstract 3
150000003883 epothilone derivatives Chemical class 0.000 abstract 3
230000007935 neutral effect Effects 0.000 abstract 3
150000003839 salts Chemical class 0.000 abstract 3
125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
229920001710 Polyorthoester Polymers 0.000 abstract 2
125000002252 acyl group Chemical group 0.000 abstract 2
235000001014 amino acid Nutrition 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
125000000129 anionic group Chemical group 0.000 abstract 2
229920006317 cationic polymer Polymers 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
238000012874 electrostatic modification Methods 0.000 abstract 2
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
125000001181 organosilyl group Chemical group [SiH3]* 0.000 abstract 2
229920000771 poly (alkylcyanoacrylate) Polymers 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
238000002560 therapeutic procedure Methods 0.000 abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 1
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 abstract 1
125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
239000004952 Polyamide Substances 0.000 abstract 1
229920002732 Polyanhydride Polymers 0.000 abstract 1
BFZKMNSQCNVFGM-UCEYFQQTSA-N Sagopilone Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@H]1C1=CC=C(SC(C)=N2)C2=C1 BFZKMNSQCNVFGM-UCEYFQQTSA-N 0.000 abstract 1
229920002472 Starch Polymers 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
239000000783 alginic acid Substances 0.000 abstract 1
229920000615 alginic acid Polymers 0.000 abstract 1
229960001126 alginic acid Drugs 0.000 abstract 1
235000010443 alginic acid Nutrition 0.000 abstract 1
150000004781 alginic acids Chemical class 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
125000003435 aroyl group Chemical group 0.000 abstract 1
125000005104 aryl silyl group Chemical group 0.000 abstract 1
125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
235000003704 aspartic acid Nutrition 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
125000002837 carbocyclic group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001768 cations Chemical class 0.000 abstract 1
239000001913 cellulose Substances 0.000 abstract 1
229920002678 cellulose Polymers 0.000 abstract 1
238000000975 co-precipitation Methods 0.000 abstract 1
238000010668 complexation reaction Methods 0.000 abstract 1
229920001577 copolymer Polymers 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000000412 dendrimer Substances 0.000 abstract 1
229920000736 dendritic polymer Polymers 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000005538 encapsulation Methods 0.000 abstract 1
125000003700 epoxy group Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
230000002209 hydrophobic effect Effects 0.000 abstract 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
229920000058 polyacrylate Polymers 0.000 abstract 1
229920002647 polyamide Polymers 0.000 abstract 1
229920001610 polycaprolactone Polymers 0.000 abstract 1
229920002721 polycyanoacrylate Polymers 0.000 abstract 1
229920000728 polyester Polymers 0.000 abstract 1
229920000137 polyphosphoric acid Polymers 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
150000004804 polysaccharides Chemical class 0.000 abstract 1
229920002635 polyurethane Polymers 0.000 abstract 1
239000004814 polyurethane Substances 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000008107 starch Substances 0.000 abstract 1
235000019698 starch Nutrition 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
229920003169 water-soluble polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nanotechnology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ARP080105366A 2007-12-10 2008-12-10 Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas. proceso. AR069638A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102007059752A DE102007059752A1 (de)	2007-12-10	2007-12-10	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone

Publications (1)

Publication Number	Publication Date
AR069638A1 true AR069638A1 (es)	2010-02-10

Family

ID=40409013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP080105366A AR069638A1 (es)	2007-12-10	2008-12-10	Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas. proceso.

Country Status (7)

Country	Link
AR (1)	AR069638A1 (fr)
DE (1)	DE102007059752A1 (fr)
PA (1)	PA8806901A1 (fr)
PE (1)	PE20091107A1 (fr)
TW (1)	TW200932220A (fr)
UY (1)	UY31521A1 (fr)
WO (1)	WO2009074274A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8206747B2 (en)	2008-06-16	2012-06-26	Bind Biosciences, Inc.	Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005725A2 (fr)	2008-06-16	2010-01-14	Bind Biosciences, Inc.	Nanoparticules polymères thérapeutiques comprenant des alcaloïdes vinca et procédés de fabrication et d’utilisation associés
US8613951B2 (en)	2008-06-16	2013-12-24	Bind Therapeutics, Inc.	Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8563041B2 (en)	2008-12-12	2013-10-22	Bind Therapeutics, Inc.	Therapeutic particles suitable for parenteral administration and methods of making and using same
ES2776126T3 (es)	2008-12-15	2020-07-29	Pfizer	Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
JP5663741B2 (ja) *	2009-03-03	2015-02-04	株式会社ナノカム	アミノ酸抱合シアノアクリレートポリマー粒子
TR201906255T4 (tr)	2009-12-11	2019-05-21	Pfizer	Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
JP5898627B2 (ja) *	2009-12-15	2016-04-06	バインドセラピューティックスインコーポレイテッド	エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
JP5965844B2 (ja)	2009-12-15	2016-08-10	バインドセラピューティックスインコーポレイテッド	高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
CA2799202C (fr)	2010-05-18	2016-07-05	Cerulean Pharma Inc.	Compositions et procedes de traitement de maladies auto-immunes et autres
US9610367B2 (en)	2010-08-24	2017-04-04	Canon Kabushiki Kaisha	Particle and contrast agent having the particle
JP6356678B2 (ja)	2012-09-17	2018-07-11	ファイザー・インク	治療用ナノ粒子を製造する方法
CA2931547A1 (fr)	2013-12-09	2015-06-18	Durect Corporation	Complexes de principes pharmaceutiquement actifs, complexes de polymeres, et compositions et procedes les impliquant
BR112016021130A2 (pt)	2014-03-14	2017-08-15	Pfizer	Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas
CA2946807A1 (fr) *	2014-05-30	2015-12-03	AbbVie Deutschland GmbH & Co. KG	Nanocapsules de poly(2-cyanoacrylate d'alkyle) hautement chargees en medicament
DE102017100317A1 (de)	2017-01-10	2018-07-12	Friedrich-Schiller-Universität Jena	Nanostrukturiertes Trägersystem zum Gentransport
CN115078292B (zh) *	2021-03-10	2025-02-11	北京大学	一种水性超分子粘附材料及其制备方法
EP4577601A1 (fr) *	2022-08-22	2025-07-02	Agfa-Gevaert Nv	Particules de résine composite absorbant la lumière infrarouge proche et rouge

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US262030A (en)		1882-08-01		Wash-stand
US252028A (en)		1882-01-10		Alonzo s
US258286A (en)		1882-05-23		Fruit-drier
US4774339A (en)	1987-08-10	1988-09-27	Molecular Probes, Inc.	Chemically reactive dipyrrometheneboron difluoride dyes
WO1990013256A1 (fr) *	1989-05-04	1990-11-15	Wisconsin Alumni Research Foundation	Procede de localisation et de traitement de tumeurs a l'aide de nouveaux complexes
US5366860A (en)	1989-09-29	1994-11-22	Applied Biosystems, Inc.	Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5274113A (en)	1991-11-01	1993-12-28	Molecular Probes, Inc.	Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en)	1994-05-20	1995-07-18	Molecular Probes, Inc.	Dibenzopyrrometheneboron difluoride dyes
US5227487A (en)	1990-04-16	1993-07-13	Molecular Probes, Inc.	Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5248782A (en)	1990-12-18	1993-09-28	Molecular Probes, Inc.	Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en)	1991-05-22	1993-02-16	Molecular Probes, Inc.	Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2684103B1 (fr)	1991-11-22	1994-09-02	Centre Nat Rech Scient	Nouveaux composes a structure guanidique et composition pharmaceutique les contenant.
DE4445065A1 (de)	1994-12-07	1996-06-13	Diagnostikforschung Inst	Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
EP1440973A3 (fr)	1995-11-17	2004-10-20	Gesellschaft für biotechnologische Forschung mbH (GBF)	Dérivés d'épothilone, procédé de production et utilisation
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
DE19728914A1 (de)	1997-07-07	1999-01-14	Basf Ag	Metallisch gefärbte Polyamide
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
JP2001512723A (ja)	1997-08-09	2001-08-28	シエーリングアクチエンゲゼルシヤフト	新規エポチロン誘導体、その製法およびその薬学的使用
WO1999018934A1 (fr) *	1997-10-09	1999-04-22	Vanderbilt University	Dispositif d'administration de microparticules ou de nanoparticules de polymeres
US6320045B1 (en)	1997-12-04	2001-11-20	Bristol-Myers Squibb Company	Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19820599A1 (de)	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999067253A2 (fr)	1998-06-22	1999-12-29	Novartis Ag	Desmethylepothilones
SE517641C2 (sv)	1998-07-02	2002-07-02	Sca Hygiene Prod Ab	Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
JP2000095758A (ja)	1998-09-18	2000-04-04	Schering Ag	近赤外蛍光造影剤および蛍光造影方法
AU2795000A (en)	1998-12-22	2000-07-12	Novartis Ag	Epothilone derivatives and their use as antitumor agents
DE19908763A1 (de)	1999-02-18	2000-08-24	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU3156700A (en)	1999-02-18	2000-09-04	Schering Aktiengesellschaft	16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19908760A1 (de)	1999-02-18	2000-08-24	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19907588A1 (de)	1999-02-22	2000-08-24	Biotechnolog Forschung Gmbh	C-21 Modifizierte Epothilone
WO2000057874A1 (fr)	1999-03-29	2000-10-05	Bristol-Myers Squibb Co.	Procede de preparation d'epothilones d'aziridinyle a partir d'epothilone d'oxiranyle
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
CA2425620A1 (fr)	1999-10-08	2001-04-19	The Scripps Research Institute	Derives d'epothilone d'alkyle-13 inferieur
JP2004500388A (ja)	2000-03-01	2004-01-08	スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ	エポチロン、その中間体およびその類似体の合成
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
DE10020517A1 (de)	2000-04-19	2001-10-25	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en)	2000-05-26	2001-12-11	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
WO2002008440A2 (fr)	2000-07-25	2002-01-31	Kosan Biosciences, Inc.	Procédé de fermentation pour épothilones
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2005500974A (ja)	2000-10-13	2005-01-13	ザユニバーシテイオブミシシッピー	エポシロン類及び関連類似体の合成
EP1358144B1 (fr)	2000-10-16	2006-12-27	R&D-Biopharmaceuticals	Composants synthetiques i d'epothilone : acyloines et derives d'acyloine a substitution asymetrique, leur procede de production et procede de production d'epothilone et de derives d'epothilone
AU2002338336A1 (en)	2001-04-03	2002-10-21	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
DE102005041860A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP2029119A2 (fr) *	2006-06-08	2009-03-04	Bayer Schering Pharma Aktiengesellschaft	Nanoparticules polymères solides fonctionnalisées pour applications diagnostiques et thérapeutiques

2007
- 2007-12-10 DE DE102007059752A patent/DE102007059752A1/de not_active Withdrawn
2008
- 2008-12-06 WO PCT/EP2008/010371 patent/WO2009074274A1/fr not_active Ceased
- 2008-12-09 TW TW097147937A patent/TW200932220A/zh unknown
- 2008-12-09 PE PE2008002025A patent/PE20091107A1/es not_active Application Discontinuation
- 2008-12-09 PA PA20088806901A patent/PA8806901A1/es unknown
- 2008-12-09 UY UY31521A patent/UY31521A1/es not_active Application Discontinuation
- 2008-12-10 AR ARP080105366A patent/AR069638A1/es unknown

Also Published As

Publication number	Publication date
TW200932220A (en)	2009-08-01
UY31521A1 (es)	2009-08-03
PE20091107A1 (es)	2009-08-29
PA8806901A1 (es)	2009-07-23
WO2009074274A1 (fr)	2009-06-18
DE102007059752A1 (de)	2009-06-18

Publication	Publication Date	Title
AR069638A1 (es)	2010-02-10	Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas. proceso.
AU2019283893B2 (en)	2022-03-24	Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
US20250312347A1 (en)	2025-10-09	Therapeutic benefit of suboptimally administered chemical compounds
AU2011348085B2 (en)	2016-12-08	Multi- API loading prodrugs
JP6280546B2 (ja)	2018-02-14	ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
ES2585262T3 (es)	2016-10-04	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
JP2018109051A (ja)	2018-07-12	多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用
CN100473381C (zh)	2009-04-01	埃坡霉素用于制备治疗与增殖过程有关的脑病的药物的用途
US20160067241A1 (en)	2016-03-10	Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US9422262B2 (en)	2016-08-23	Compounds and methods for treating diseases mediated by protease activated receptors
RU2003130377A (ru)	2005-03-10	Комбинация аналогов эпотилона и химиотерапевтических агентов для лечения пролиферативных заболеваний
CN109415360A (zh)	2019-03-01	用于抑制shp2活性的化合物和组合物
PE20050664A1 (es)	2005-10-26	Derivados de 1h-imidazo[4,5-c]quinolina
CN108349968A (zh)	2018-07-31	抗菌治疗剂和预防剂
AR077935A1 (es)	2011-10-05	Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20090370A1 (es)	2009-04-30	Derivados de heterociclo fusionado como inhibidores de quinasa
CA2829241A1 (fr)	2012-10-04	Formulations thermosensibles, mucoadhesives ou dermoadhesives et ameliorant la penetration pour l'administration topique de produits therapeutiques
RU2003128311A (ru)	2005-03-10	Способ лечения резистентных опухолей с применением аналогов эпотилона
CA2907603A1 (fr)	2014-10-02	Derives de 2-amino-ethan-1-one et leur utilisation en tant qu'inhibiteurs de replication virale
KR20170047341A (ko)	2017-05-04	헌팅틴 단백질을 영상화하기 위한 프로브
JP2003528096A5 (fr)	2007-12-27
KR20130123301A (ko)	2013-11-12	히스톤 디아세틸라아제의 저해제들로서 유용한 거대고리 화합물들
PE20091083A1 (es)	2009-07-23	Moduladores tieno- y furo- pirimidina del receptor de histamina h4
CA3006189A1 (fr)	2017-06-01	Methodes et compositions d'inhibition de comt
Pkn et al.	2016	Thiazoles as potent anticancer agents: A review

Legal Events

Date	Code	Title	Description
2011-12-19	FB	Suspension of granting procedure